New reflexiones about renal vascular medicine;Nuevas reflexiones en torno a la medicina renal-vascular

Nefrologia

Volumn 23, Issue 2, 2003, Pages 97-102

  Diez J ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; EDITORIAL; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; INSULIN RESISTANCE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MORTALITY; OBESITY; PREVALENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL TIME; VASCULAR DISEASE; EDUCATION; HEALTH SERVICE; HUMAN; KIDNEY CIRCULATION; KIDNEY DISEASE; NEPHROLOGY; RESEARCH; RISK FACTOR;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETIC NEPHROPATHIES; HEALTH SERVICES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; NEPHROLOGY; PREVALENCE; RENAL CIRCULATION; RESEARCH; RISK FACTORS; VASCULAR DISEASES;

EID: 4544263045     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (66)

1. Sociedad Española de Nefrología: El libro blanco de la Nefrología española (III). Nefrologĩa 20: 396-402, 2000.
2. Díez J: La nefrología clínica: ¿medicina renal, medicina vascular, o ambas? Nefrología 21: 429-430, 2001.
3. (www.cdc.gov/nccdph/vd/international.htm: www.who.it/dsa/cat98/card8.htm) .
4. www.ine.es/inebase/cgi/um)
5. Cases A: Enfermedad macro y microvascular en la diabetes mellitus tipo 2. Nefrología 22: 406-411, 2002.
6. Guallar-Castillón. P, Banegas JR, García MJ, Gutiérrez-Fisac JL, López E, Rodríguez-Artalejo F: Asociación de la enfermedad cardiovascular con el sobrepeso y la obesidad en España. Med Clín (Barc) 118: 616-618, 2002.
7. Lakatta EG, Levy D: Arterial and cardiac aging: major shareholders in cardiovascular disease entreprises. Part I: aging arteries: a «set up» for vascular diseases. Circulation 107: 139-146, 2003.
8. Comité de Registro de la SEN y Registros Autonómicos: informe de diálisis y trasplante de la Sociedad Española de Nefrología y Registros Autonómicos, año 2000. Nefrología 22: 310-317, 2002.
9. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study. J Am Soc Nephrol 13: 1918-1927, 2002.
10. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BI, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Keffer MA, Wenger NK, Wilson PW, Wright JT Jr: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32: 853-906, 1998.
11. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62: 1524-1538, 2002.
12. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM: Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107: 87-92, 2003.
13. London GM: Vascular disease and atherosclerosis in uremia. Blood Purif 19: 139-142, 2001.
14. Campistol JM: Uremic myopathy. Kidney Int 62: 1901-1913, 2002.
15. London GM: Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant 17 (Supl. 1): 29-36, 2002.
16. Stenvinkel P, Heimburger O, Paultre F, Iczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 51: 1899-1911, 1999.
17. Bloembergen WE, Hakim RM, Stannard DC, Held PJ, Wolfe RA, Agodoa LY, Port FK: Relationship of dialysis membrane and cause-specific mortality. Am J Kidney Dis 33: 1-10, 1999.
18. Dimény EM: Cardiovascular disease after renal transplantation. Kidney Int 61 (Supl. 80): S78-S84, 2002.
19. Paparello J, Kshirsagar A, Batlle D: Comorbidity and cardiovascular risk factors in patients with chronic kidney disease. Semin Nephrol 22: 494-506, 2002.
20. Ruggenenti P, Schieppati A, Remuzzi G: Progression, remission, regression of chronic renal diseases. Lancet 357: 1601-1608, 2001.
21. Wanner C, Krane V, Metzger T, Quaschning T: Lipid changes and statins in chronic renal insufficiency and dialysis. J Nephrol 14 (Supl. 4): S76-S80, 2001.
22. Schena A, Di Paolo S, Morrone LF, Resta F, Stallone G, Schena FP: Are lipid-dependent indicators of cardiovascular risk affected by renal transplantation? Clin Transplant 14: 139-146, 2000.
23. Kasiske BL, Klinger D: Cigarette smoking in renal transplant recipients. J Am Soc Nephrol 11: 753-759, 2000.
24. Collins AJ, Li S, Ma JZ, Herzog C: Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 38 (4 Supl. 1): S26-S29, 2001.
25. Praga M: Slowing the progression of renal failure. Kidney Int 61 (Supl. 80): S18-S22, 2002.
26. Meier-Kriesche HU, Vaghela M, Thambuganipalle R, Friedman G, Jacobs M, Kaplan B: The effect of body mass index on long-term renal allograft survival. Transplantation 68: 1294-1297, 1999.
27. Weinstock Brown W, Kenae WF: Proteinuria and cardiovascular disease. Am J Kidney Dis 38 (Supl. 1): S8-S13, 2001.
28. Ruilope LM, Van Veldhuisen DJ, Ritz E, Lüscher TF: Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol 38: 1782-1787, 2001.
29. Ritz E, Dikow R, Ruilope LM: Renal dysfunction as a cardiovascular risk factor. Curr Hypertens Res 4: 365-368, 2002.
30. Diercks GF, Van Boven AJ, Hillege JL, De Jong PE, Rouleau JL, Van Gilst WH: The importance of microalbuminuria as a cardiovascular risk indicator: a review. Can J Cardiol 18: 525-535, 2002.
31. Bostom AG, Lathrop L: Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology and potential relationship to arteriosclerotic outcomes. Kidney Int 52: 10-20, 1997.
32. Kronenberg F, Utermann G, Dieplinger H: Lipoprotein(a) in renal disease. Am J Kidney Dis 27: 1-25, 1996.
33. Homocysteine Studies Collaboration: Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288: 2015-2022, 2002.
34. Scanu AM: The role of lipoprotein(a) in the pathogenesis of atherosclerotic cardiovascular disease and its utility as predictor of coronary heart disease events. Curr Cardiol Rep 3: 385-390, 2001.
35. Parving HH, Hovind P, Rossing K, Andersen S: Evolving strategies for renoprotection: diabetic nephropathy. Curr Opin Nephrol Hypertens 10: 515-522, 2001.
36. Taal MW, Brenner BM: Evolving strategies for renoprotection: non-diabetic chronic renal disease. Curr Opin Nephrol Hypertens 10: 523-531, 2001.
37. Campbell RC, Remuzzi G: Halting the progression of renal disease: where we stand? Nefrología 22: 303-305, 2002.
38. Luft FC: Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases. Curr Opin Nephrol Hypertens 11: 59-66, 2002.
39. Vogt L, Navis G, De Zeeuw D: Renoprotection: a matter of blood pressure reduction or agent-characteristics? J Am Soc Nephrol 13 (Supl. 3): S202-S207, 2002.
40. Elisaf M, Mikhailidis DP: Statins and renal function. Angiology 53: 493-502, 2002.
41. Keane WF: The role of lipids in renal disease: future challenges. Kidney Int 57 (Supl. 75): S-27-S-31, 2000.
42. Wheeler DC: Statins and the kidney. Curr Opin Nephrol Hypertens 7: 579-584, 1998.
43. Obrador GT, Pereira BJ, Kausz AT: Chronic kidney disease in the United States: an underrecognized problem. Semin Nephrol 22: 441-448, 2002.
44. Tuttle KR: Ischemic nephropathy. Curr Opin Nephrol Hypertens 10: 167-173, 2001.
45. Marín R, Gorostidi M, Pobes A: Hipertensión arterial y enfermedad vascular renal: nefroangiosclerosis. Nefrología 22 (Supl. 1): 36-45, 2002.
46. Kinchen KS, Sadler J, Fink N, Brookmeyer R, Klag MJ, Levey AS, Powe NR: The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med 137: 479-486, 2002.
47. Dikow R, Adamczak M, Henríquez DE, Ritz E: Strategies to decrease cardiovascular mortality in patients with end-stage renal disease. Kidney Int 61 (Supl. 80): S-5-S10, 2002.
48. Royle EM, Fowkes FG: Rationalizing evidence for vascular medicine. Vasc Med 3: 1-2, 1998.
49. Olin JW: Is vascular medicine a viable specialty? Vasc Med 6: 129-131, 2001.
50. West JA: Cost-effective strategies for the management of vascular disease. Vasc Med 2: 25-29, 1997.
51. (http://www.senefro.org/guia.htm)
52. Varies autores. Nefrología Clínica. En: Sociedad Española de Nefrología (eds.). Normas de actuación clínica en Nefrologia. 1999.
53. Withcomb ME, Walter DL: Research training in six selected internal medicine fellowship programs. Ann Intern Med 133: 800-807, 2000.
54. Pogue VA, Morris KC, Dillard MG: Kidney disease physician workforce: where is the emerging pipeline? J Natl Med Assoc 94 (8 Supl.); 39S-44S, 2002.
55. Matesanz R: La docencia postgraduada de la nefrologia en España. Nefrología 22: 399-405, 2002.
56. Varmus H: Getting ready for gene-based medicine. N Engl J Med 347: 1526-1527, 2002.
57. Eikmans M, Baelde HJ, De Heer E, Brujin JA: RNA expression profiling as prognostic tool in renal patients: toward nephrogenomics. Kidney Int 62: 1125-1135, 2002.
58. Knepper MA: Proteomics and the kidney. J Am Soc Nephrol 13: 1398-1408, 2002.
59. Zoccali C: Cardiorenal risk as a new frontier of nephrology: research needs and areas for intervention. Nephrol Dial Transplant 17 (Supl. 11): 50-54, 2002.
60. Textor SC, Wilcox CS: Ischemic nephropathy/azotemic renovascular disease. Semin Nephrol 20: 489-502, 2000.
61. Hsu CY, Cherton GM, Curhan GC: Methodological issues in studying the epidemiology of mild to moderate chronic renal insufficiency. Kidney Int 61: 1567-1576, 2002.
62. Crook ED: The role of hypertension, obesity, and diabetes in causing renal vascular disease. Am J Med Sci 317: 183-188, 1999.
63. Hayden PS, Iyengar SK, Schelling JR, Sedor JR: Kidney disease, genotype and the pathogenesis of vasculopathy. Curr Opin Nephrol Hypertens 12: 71-78, 2003.
64. Loscalzo J, Balaban R, Becker LB, Ginsburg GS, Hachinski VC, Hall JE, Heistad DD, Leinwand LA, Lenfant CJ, Marban E, Olson EN, Schwartz SM: Task force on strategic research direction. Basic science subgroup key science topics report. Circulation 106: 149e-161e, 2002.
65. Lamas S: Los nefrólogos que elegimos el laboratorio. Nefrología 22: 106-107, 2002.
66. st century. Am J Kidney Dis 35 (4 Supl. I): S93-S96, 2000.